There are currently no disease-targeted treatments for cognitive or behavioral symptoms in patients with behavioral variant frontotemporal dementia (bvFTD).
Objective:
To determine the effect of tolcapone, a specific inhibitor of Catechol-O-Methyltransferase (COMT), in patients with bvFTD.
Methods:
In this randomized, double-blind, placebo-controlled, cross-over study at two study sites, we examined the effect of tolcapone on 28 adult outpatients with bvFTD. The primary outcome was reaction time on the N-back cognitive test. As an imaging outcome, we examined differences in the resting blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) signal intensity between subjects on placebo versus tolcapone performing the N-back test. Secondary outcomes included measures of cognitive performance and behavioral disturbance using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Neuropsychiatric Inventory-Questionnaire (NPI-Q), and Clinical Global Impressions scale (CGI).
Results:
Tolcapone was well tolerated and no patients dropped out. The most frequent treatment-related adverse event during tolcapone treatment was elevated liver enzymes (21%). There were no significant differences between tolcapone treatment and placebo in the primary or imaging outcomes. However, there were significant differences between RBANS total scores (p < 0.01), NPI-Q total scores (p = 0.04), and CGI total scores (p = 0.035) between treatment conditions which were driven by differences between baseline and tolcapone conditions. Further, there was a trend toward significance between tolcapone and placebo on the CGI (p = 0.078).
Conclusions:
Further study of COMT inhibition and related approaches with longer duration of treatment and larger sample sizes in frontotemporal lobar degeneration-spectrum disorders may be warranted.
HuotariM, SanthaM, LucasLR, KarayiorgouM, GogosJA, MannistoPT (2002) Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther303, 1309–1316.
11.
EngelborghsS, VloeberghsE, Le BastardN, Van BuggenhoutM, MarienP, SomersN, NagelsG, PickutBA, De DeynPP (2008) The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int52, 1052–1060.
O’DonnellBF, DrachmanDA, BarnesHJ, PetersonKE, SwearerJM, LewRA (1992) Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol5, 45–52.
15.
ManoochehriM, HueyED (2012) Diagnosis and management of behavioral issues in frontotemporal dementia. Curr Neurol Neurosci Rep12, 528–536.
16.
CleophasTJ, ZwindermanAH (2002) Crossover studies with continuous variables: Power analysis. Am J Ther9, 69–73.
17.
AshareRL, ValdezJN, RuparelK, AlbeldaB, HopsonRD, KeefeJR, LougheadJ, LermanC (2013) Association of abstinence-induced alterations in working memory function and COMT genotype in smokers. Psychopharmacology (Berl)230, 653–662.
18.
BorgesN (2005) Tolcapone in Parkinson’s disease: Liver toxicity and clinical efficacy. Expert Opin Drug Saf4, 69–73.
19.
BonifatiV, MecoG (1999) New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson’s disease. Pharmacol Ther81, 1–36.
20.
RandolphC, TierneyMC, MohrE, ChaseTN (1998) The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity. J Clin Exp Neuropsychol20, 310–319.
21.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2314.
22.
MattayVS, GoldbergTE, FeraF, HaririAR, TessitoreA, EganMF, KolachanaB, CallicottJH, WeinbergerDR (2003) Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A100, 6186–6191.
23.
MattayVS, CallicottJH, BertolinoA, HeatonI, FrankJA, CoppolaR, BermanKF, GoldbergTE, WeinbergerDR (2000) Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage12, 268–275.
24.
HueyED, GarciaC, WassermannEM, TierneyMAM, GrafmanJ (2008) Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry69, 1981–1982.
25.
GuyW (1976) Clinicians’ Global Impression of Change (CGIC), National Institute of Mental Health, Rockville, MD.
26.
PowerJD, CohenAL, NelsonSM, WigGS, BarnesKA, ChurchJA, VogelAC, LaumannTO, MiezinFM, SchlaggarBL, PetersenSE (2011) Functional network organization of the human brain. Neuron72, 665–678.
27.
Tzourio-MazoyerN, LandeauB, PapathanassiouD, CrivelloF, EtardO, DelcroixN, MazoyerB, JoliotM (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage15, 273–289.
28.
HastieT, TibshiraniR, FriedmanJH (2009) The elements of statistical learning: Data mining, inference, and prediction, Springer, New York.
MazeiMS, PlutoCP, KirkbrideB, PehekEA (2002) Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res936, 58–67.
31.
MoronJA, BrockingtonA, WiseRA, RochaBA, HopeBT (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines. J Neurosci22, 389–395.
32.
MunafoMR, BowesL, ClarkTG, FlintJ (2005) Lack of association of the COMT (Val(158/108) Met) gene and schizophrenia: A meta-analysis of case-control studies. Mol Psychiatry10, 765–770.
33.
RujescuD, GieglingI, GietlA, HartmannAM, MollerHJ (2003) A functional single nucleotide polymorphism (V158M) in the COMT gene is associated with aggressive personality traits. Biol Psychiatry54, 34–39.
34.
LottaT, VidgrenJ, TilgmannC, UlmanenI, MelenK, JulkunenI, TaskinenJ (1995) Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry34, 4202–4210.
35.
EganMF, GoldbergTE, KolachanaBS, CallicottJH, MazzantiCM, StraubRE, GoldmanD, WeinbergerDR (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A98, 6917–6922.
36.
GoldbergTE, EganMF, GscheidleT, CoppolaR, WeickertT, KolachanaBS, GoldmanD, WeinbergerDR (2003) Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry60, 889–896.
37.
DiamondA, BriandL, FossellaJ, GehlbachL (2004) Genetic and neurochemical modulation of prefrontal cognitive functions in children. Am J Psychiatry161, 125–132.
38.
NolanKA, BilderRM, LachmanHM, VolavkaJ (2004) Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: Differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry161, 359–361.
39.
RosaA, PeraltaV, CuestaMJ, ZarzuelaA, SerranoF, Martinez-LarreaA, FananasL (2004) New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry161, 1110–1112.
ChongDJ, SuchowerskyO, SzumlanskiC, WeinshilboumRM, BrantR, CampbellNR (2000) The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson’s disease. Clin Neuropharmacol23, 143–148.
42.
BhaktaSG, LightGA, TalledoJA, BalvanedaB, HughesE, AlvarezA, RanaBK, YoungJW, SwerdlowNR (2017) Tolcapone-enhanced neurocognition in healthy adults: Neural basis and predictors. Int J Neuropsychopharmacol20, 979–987.
43.
ApudJA, WeinbergerDR (2007) Treatment of cognitive deficits associated with schizophrenia: Potential role of catechol-O-methyltransferase inhibitors. CNS Drugs21, 535–557.
44.
MoreauJL, BorgulyaJ, JenckF, MartinJR (1994) Tolcapone: A potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol5, 344–350.
45.
FavaM, RosenbaumJF, KolskyAR, AlpertJE, NierenbergAA, SpillmannM, MooreC, RenshawP, BottiglieriT, MorozG, MagniG (1999) Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol19, 329–335.
HuotariM, GainetdinovR, MannistoPT (1999) Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats. Pharmacol Toxicol85, 233–238.
48.
MaserT, RichM, HayesD, ZhaoP, NagulapallyAB, BondJ, Saulnier ShollerG (2017) Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma. Cancer Med6, 1341–1352.
49.
Di GiovanniS, EleuteriS, PaleologouKE, YinG, ZweckstetterM, CarruptPA, LashuelHA (2010) Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem285, 14941–14954.
50.
RockwoodK (2004) Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry75, 677–685.
